Eesti - eesti - Ravimiamet

laboratorios hipra s.a. - tokoferool+naatriumseleniit - süstelahus - 50mg+1,5mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

laboratorios hipra s.a. - oksütetratsükliin - süstelahus - 200mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

laboratorios karizoo s.a. - halofuginoon - suukaudne lahus - 0,5mg 1ml 500ml 1tk; 0,5mg 1ml 250ml 1tk; 0,5mg 1ml 1000ml 1tk

Eesti - eesti - Ravimiamet

laboratorios hipra s.a. - escherichia coli+clostridium - süstesuspensioon - 100ml 1tk; 20ml 1tk; 250ml 1tk; 50ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - sead - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Euroopa Liit - eesti - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - sead - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Euroopa Liit - eesti - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - risperidone - skisofreenia - psühhoeptikumid - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Eesti - eesti - Ravimiamet

laboratorios karizoo s.a. - isofluraan - inhalatsiooniaur, vedelik - 1000mg 1g 250ml 1tk

Eesti - eesti - Ravimiamet

laboratorios basi industria farmaceutica s.a. - metoklopramiid - süste-/infusioonilahus - 5mg 1ml 2ml 50tk

Eesti - eesti - Ravimiamet

laboratorios basi industria farmaceutica s.a. - paratsetamool - infusioonilahus - 10mg 1ml 100ml 50tk